CLL | Tumor

Your Chronic Lymphocytic Leukemia (CLL) Diagnosis

April 16th 2021, 12:00pm


Navigating life with blood cancer

Sponsored Content: CALQUENCE® (acalabrutinib) for Patients with Chronic Lymphocytic Leukemia (CLL)

March 17th 2021, 12:00pm


An interview with Dr. Jennifer K. Lue, Assistant Professor of Medicine, Center for Lymphoid Malignancies, Division of Hematology and Oncology, Columbia University Irving Medical Center

Imbruvica Plus Novel Agent May Improve Progression-Free Survival in Chronic Lymphocytic Leukemia

March 3rd 2021, 7:00pm


Patients treated with Imbruvica plus TG-1101 had an overall response rate of 83% compared with 65% in those treated with Imbruvica alone.

Marialice’s Story with Chronic Lymphocytic Leukemia (CLL)

February 19th 2021, 9:30pm


Treating CLL with CALQUENCE® (acalabrutinib)

Friday Frontline: First Patient to Receive CAR-T Cell Therapy Dies, Cancer Organizations Appeal to President for COVID-19 Vaccine Priority Access, and More

February 19th 2021, 4:00pm


From the death of Bill Ludwig, the first patient to receive CAR-T cell therapy to treat his end-stage CLL, to a letter to the President urging him to grant patients with cancer and survivors priority access to the COVID-19 vaccine, here’s what’s happening in the cancer space this week.

Jim’s Story with Chronic Lymphocytic Leukemia (CLL)

February 19th 2021, 1:00pm


Treating CLL with CALQUENCE® (acalabrutinib)

Adding to the Regimen: NCCN Updates in Leukemia and Lymphoma

February 15th 2021, 4:00pm


The NCCN has updated its recommendations for chronic lymphocytic leukemia and small lymphocytic lymphoma to now include Brukinsa as a first- and second-line therapy in a subgroup of patients.

For Younger Patients, CAR T-Cell Therapy Could Play a Role in CLL Treatment

January 18th 2021, 4:00pm


In an interview, Dr. Matthew Davids of the Dana-Farber Cancer Institute discusses the future of CAR T-Cell therapy in the treatment of younger patients with chronic lymphocytic leukemia.

Areas Patients with CLL Can Focus On to Maintain Their Health Beyond Treatment

January 15th 2021, 10:00pm


In a recent interview with CURE®, a medical oncologist from the Dana-Farber Cancer Institute discussed why it’s important for patients with CLL, regardless of their treatment plans, to keep up on vaccinations and maintain a regular cancer screening schedule.

Adding Copiktra to Standard of Care Chemotherapy Combination in CLL Could Improve Outcomes, But Not Without Toxicities

January 14th 2021, 3:00pm


In a recent interview with CURE®, a medical oncologist from the Dana-Farber Cancer Institute in Boston discussed how the addition of Copiktra to a three-drug chemotherapy combination improved outcomes in patients with CLL, with more than half achieving complete remission.